Trial Profile
A Randomized, Double-blinded, Placebo-controlled, Sequential, Single Ascending Dose Evaluation of the Safety and Pharmacokinetics of VBY-376 in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jan 2014
Price :
$35
*
At a glance
- Drugs VBY 376 (Primary)
- Indications Hepatic fibrosis; Hepatitis C
- Focus Adverse reactions
- Sponsors Virobay
- 31 Jul 2008 Status changed from recruiting to completed (based on information from ClinicalTrials.gov).
- 22 Nov 2007 New trial record.